Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial

Jill J. F. Belch; John K. Drury; Hilary Capell; Charles D. Forbes; Peter Newman; Fiona McKenzie; Paul Leiberman; Colin R. M. Prentice

doi:10.1016/S0140-6736(83)91624-0

Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial

Jill J. F. Belch, John K. Drury, Hilary Capell, Charles D. Forbes, Peter Newman, Fiona McKenzie, Paul Leiberman, Colin R. M. Prentice

Research output: Contribution to journal › Article › peer-review

136 Citations (Scopus)

Abstract

Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.

Original language	English
Pages (from-to)	313-315
Number of pages	3
Journal	Lancet
Volume	1
Issue number	8320
DOIs	https://doi.org/10.1016/S0140-6736(83)91624-0
Publication status	Published - 1983

Access to Document

10.1016/S0140-6736(83)91624-0

Cite this

@article{092551fbbe1541fc94aa6f7464a496fe,

title = "Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial",

abstract = "Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.",

author = "Belch, {Jill J. F.} and Drury, {John K.} and Hilary Capell and Forbes, {Charles D.} and Peter Newman and Fiona McKenzie and Paul Leiberman and Prentice, {Colin R. M.}",

year = "1983",

doi = "10.1016/S0140-6736(83)91624-0",

language = "English",

volume = "1",

pages = "313--315",

journal = "Lancet",

issn = "0140-6736",

publisher = "ELSEVIER SCIENCE INC",

number = "8320",

}

TY - JOUR

T1 - Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome

T2 - a double-blind controlled trial

AU - Belch, Jill J. F.

AU - Drury, John K.

AU - Capell, Hilary

AU - Forbes, Charles D.

AU - Newman, Peter

AU - McKenzie, Fiona

AU - Leiberman, Paul

AU - Prentice, Colin R. M.

PY - 1983

Y1 - 1983

N2 - Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.

AB - Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.

U2 - 10.1016/S0140-6736(83)91624-0

DO - 10.1016/S0140-6736(83)91624-0

M3 - Article

C2 - 6130329

SN - 0140-6736

VL - 1

SP - 313

EP - 315

JO - Lancet

JF - Lancet

IS - 8320

ER -

Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial

Abstract

Access to Document

Fingerprint

Cite this